NCT05616221Phase 2Completed

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Study sponsor: Armata Pharmaceuticals, Inc. · ARMP

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-07-17Actual
Enrollment · participants48Actual
Source updated2026-01-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview